Biomarker ID | 506 |
PMID | 20035634 |
Year | 2009 |
Biomarker | PDIA3 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Gleason Score 8-10 |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-N-glycan trimming in the ER and calnexin/calreticulin cycle, Antigen processing: cross presentation, Antigen processing and presentation, Asparagine N-linked glycosylation, Protein processing in the endoplasmic reticulum |
Experiment | Gleason Score 6 Vs Gleason Score (8-10) |
Type of Biomarker | Prognostic |
Cohort | 65 RNA samples derived from 13 benign and 52 prostate cancer tissue comprising 25 samples with Gleason Score (GS) 6 and 27 samples with GS 8-10 |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | qRT-PCR: p=0.00167 |
Method Used | qRT-PCR and Immunohistochemistry |
Clinical | No |
Remarks | Another 2500 differentially expressed genes between prostate cancer and benign samples are available from supplementry material of the paper |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | PDIA3 |